Skip to main content
. Author manuscript; available in PMC: 2016 Jan 1.
Published in final edited form as: Cancer Immunol Res. 2014 Oct 30;3(1):68–84. doi: 10.1158/2326-6066.CIR-14-0192

Figure 2. PSMA is expressed on the vasculature of primary and metastatic cancer.<.

Figure 2

br>(A) Representative staining for PSMA (top row), as well as PSMA and the endothelial marker, CD34 (bottom row). Sequential sections were cut and stained for either PSMA alone, or PSMA with CD34. Images in each column depict the same region within the same core. Original magnification, 200×; scale bar, 50 μm. (B) A heat map showing the presence or absence of PSMA on the vasculature of tumors taken from subjects with resected ovarian cancer (n = 15). (C) Representative tumor core staining for both PSMA (red) and CD34 (brown). Black arrows indicate CD34+ vessels that are negative for PSMA expression; red arrows indicate dual-positive (CD34+PSMA+) vessels. (D) Level of PSMA expression on tumor endothelial cells (CD45−CD31+) from three subjects with gynecologic cancer. Tumor endothelial cells were collected by CD45 depletion followed by CD31 enrichment. PSMA was detected by humanized J591 Ab (open histogram) and compared with human IgG control (closed histogram). (E) The percentage of PSMA-positive CD45−CD31+ endothelial cells remaining after overnight co-culture with CAR T cells (E:T = 1:1). Percentage = treated/untreated × 100. (F) IFNγ production by P28BBζ T cells after co-culture with CD31 enriched or depleted targets (E:T = 1:1). Culture supernatants were collected at 18 h and IFNγ was measured by ELISA.